Table 4. Comprehensiveness of medication exposure assessment.
| Prescription medication name | OTC name | Exposure time defined | Medication strength | Dose/frequency | Participant reported indication | Participant reported duration of therapy | Past medication use | Consent for PBS/RPBS linkage | Questions consistent longitudinally | |
|---|---|---|---|---|---|---|---|---|---|---|
| 45 & Up [11] | B, L | B, L | B, L | B** | B # | B, L | Y | |||
| AIBL [15] | B,L | B, L | B*, L* | B, L | B, L | B, L | Y | |||
| ALSA [12] | B, L | B, L | B, L | B, L** | B | B, L | B, L | L ### | L | |
| ALSWH [21] | L | B, L | L** | B # | L | |||||
| AusDiab [16] | L | B*, L | L | L | B # | |||||
| BMES [17] | B, L | B, L | B, L* | L | L | B, L | B # , ## , L # , ## | L | ||
| CLS [18] | B*, L* | L # | ||||||||
| CHAMP [22] | B, L | B, L | B, L | B, L | B, L | B, L | B # , L # | Y | ||
| HIMS [23] | L | L | B, L* | L | L | L # | ||||
| HCS [13] | B, L | B, L | B*, L* | B, L | B, L | B, L | Y | |||
| MELSHA [14] | B | B | B*** | B | B | |||||
| SADLS [19] | B, L | B, L | B, L | B, L | B, L | Y | ||||
| Syd-MAS [20] | B, L | B, L | B*, L* | B, L | B, L | B # , L # | B | Y |
B: Baseline
L: Longitudinal waves
Y: Medication questions consistent during all waves of study
OTC: ‘Over the Counter’ medication (ie non-prescription medications, including vitamins, herbal supplements etc)
PBS/RPBS: Pharmaceutical Benefits Scheme/ Repatriation Pharmaceutical Benefits Scheme (pharmaceutical administrative claims data)
* Exposure time = “current”
** strength of prescription medications via PBS data
*** for analgesic or psychotropic medicines only (defined list)
# “Ever” use of a small number of named medications of interest
## “Any other tablets taken for more than 3 months in the past”
### Wave 2: confirm persistent use of medications identified at baseline